Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) | RFA NS 25 025

Frequently Asked Questions (FAQs)

What is this NIH funding opportunity?

This opportunity is an NIH R21 exploratory/developmental research grant titled "Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed)." It is intended to support early-stage, high-impact projects that can accelerate progress in understanding, diagnosing, monitoring, and treating GBS and CIDP.

What is the Funding Opportunity Number (FOA) and CFDA listing?

The Funding Opportunity Number is RFA-NS-25-025, and the CFDA listing is 93.853.

What type of funding mechanism is this?

The mechanism is an R21, which is generally used for exploratory/developmental research, proof-of-concept work, and development of new approaches rather than large, definitive studies.

Are clinical trials allowed under this FOA?

No. The FOA is explicitly labeled "Clinical Trial Not Allowed." Proposed studies should be designed so they do not meet NIH's definition of a clinical trial.

If clinical trials are not allowed, what kinds of human-focused studies might still fit?

Based on the description provided, studies such as mechanistic human research, analyses of human biospecimens, and observational or translational work may still be relevant, as long as the project is structured appropriately and remains outside NIH's clinical trial definition.

What is the central goal of the initiative?

The central goal is to accelerate research explaining how immune-mediated processes lead to nerve damage and dysfunction in GBS and CIDP, and how those processes might be intercepted, measured, or reversed to support better diagnosis, monitoring, and treatment strategies.

What diseases and conditions are the focus of this program?

The focus is on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), particularly their immune-mediated biology and related clinical challenges.

What kinds of research topics are considered responsive?

Responsive topics include exploratory work addressing immunological mechanisms (immune pathways and cellular players driving inflammation, demyelination, axonal injury, and impaired nerve signaling), genetic and epigenetic contributors to susceptibility and outcomes, improved animal or cellular models, biomarker discovery and development, and studies supporting novel treatments or clarifying mechanisms of action of existing treatments.

Is biomarker research specifically encouraged?

Yes. Biomarker discovery and development is highlighted as a major area of interest, including diagnostic biomarkers, prognostic biomarkers, biomarkers for patient stratification and disease activity tracking, and treatment-response biomarkers.

What types of biomarkers are mentioned as priorities?

The opportunity mentions diagnostic biomarkers (to improve accuracy or speed of diagnosis), biomarkers that predict prognosis or stratify patients, biomarkers that track disease activity over time, and treatment-response biomarkers that can indicate whether a therapy is working earlier than current clinical assessments.

Does the FOA support development of animal or cellular models?

Yes. The announcement encourages development of novel animal models and cellular model systems that better capture key features of GBS or CIDP to enable faster testing of hypotheses about disease triggers and immune-nerve interactions.

Can applicants propose research on treatments?

Yes. The initiative supports research into novel treatments as well as studies clarifying the mechanisms of action of existing treatments, including why therapies may work for some patients but not others and how treatment timing or biological context may affect outcomes.

What does "exploratory/developmental" mean in the context of this R21?

In this opportunity, "exploratory" emphasizes innovative ideas, proof-of-concept studies, and development of new approaches intended to generate decisive preliminary data and move the field forward, rather than conducting large, definitive clinical efficacy trials.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic institutions and organizations, as well as additional categories explicitly called out in the listing, including certain non-U.S. (foreign) organizations as indicated in the opportunity description.

Which government entities are eligible?

Eligible government applicants include state governments, county governments, city or township governments, and special district governments.

Are educational institutions eligible?

Yes. Eligible applicants include independent school districts, public and state-controlled institutions of higher education, and private institutions of higher education.

Are tribal governments and tribal organizations eligible?

Yes. Federally recognized Native American tribal governments are eligible, and Native American tribal organizations that are not federally recognized tribal governments are also included.

Are nonprofit organizations eligible?

Yes. Nonprofit organizations are eligible whether or not they have 501(c)(3) status, as described in the opportunity information.

Are for-profit organizations eligible?

Yes. For-profit organizations are included as eligible applicants (other than small businesses), and small businesses are also included under the general eligibility umbrella listed.

Are public housing authorities eligible?

Yes. Public housing authorities and Indian housing authorities are listed as eligible entities.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly included among the additional eligible applicant categories.

Are Historically Black Colleges and Universities (HBCUs) and other serving institutions eligible?

Yes. The listing calls out multiple serving institution categories, including HBCUs, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are included among the eligible applicant categories.

Are non-U.S. (foreign) organizations eligible?

The opportunity description indicates that non-U.S. (foreign) organizations are among the eligible applicant categories, suggesting international contributors may participate when permitted.

What is the funding instrument type and research category?

The funding instrument type is a Grant, and the category is Health.

When was this opportunity created?

The opportunity record shows a created date of 2024-11-13.

What is the application closing date?

The original application closing date shown is 2025-10-03.

What is the maximum award amount shown in the opportunity record?

The listing shows an award ceiling of $3,000,000, representing the maximum amount shown in the opportunity record.

Does the listing specify how many awards NIH expects to make?

No. The record does not specify the expected number of awards, which suggests the number of funded projects may depend on the quantity and quality of applications and the funds NIH allocates to this initiative.

Should applicants assume they can request up to the full award ceiling?

Not necessarily. While the opportunity record shows an award ceiling of $3,000,000, applicants are advised (in the provided description) to verify the allowed budget structure and project period expectations for the R21 mechanism in the full FOA, since R21 budgets are often constrained by mechanism-specific guidelines and institute policies.

What kinds of applications are likely to be competitive based on the description?

Applications are likely to be strongest when they clearly identify an important gap in understanding or clinical need, propose a rigorous and feasible exploratory approach to generate decisive preliminary data, and explain how the work could translate into better diagnostics, improved monitoring, clearer patient stratification, or more effective therapeutic strategies, while staying within the "no clinical trial" boundary.

What is the overall purpose of this R21 initiative in practical terms?

In practical terms, this initiative is meant to jump-start creative, early-stage research that opens new directions in GBS and CIDP science and moves the field toward clearer disease biology and, ultimately, better ways to diagnose, monitor, and treat these conditions.